Emerging Synthetic Drug Intoxications: Toxidrome Recognition, Emergency Stabilization, and Neuropsychiatric Outcomes
DOI:
https://doi.org/10.64784/347Palabras clave:
new psychoactive substances, synthetic drugs, clinical toxicology, emergency medicine, synthetic cannabinoids, synthetic cathinones, nitazenes, xylazine, toxidrome, intoxication, naloxone, psychosis, delirium, neuropsychiatric complications, polysubstance exposureResumen
Emerging synthetic drugs and new psychoactive substances represent a growing challenge for emergency medicine, clinical toxicology, and psychiatry due to their rapidly changing composition, variable potency, frequent polysubstance exposure, and capacity to produce overlapping toxicological syndromes. This study analyzed the clinical presentation, emergency stabilization strategies, and neuropsychiatric complications associated with synthetic cannabinoids, synthetic cathinones, nitazenes, designer benzodiazepines, xylazine, and other emerging psychoactive compounds. A structured analytical review based on the Scientific Method was conducted using recent clinical studies, systematic reviews, toxicological reports, and emergency medicine publications. The evidence showed that these substances can produce neurological, cardiovascular, respiratory, metabolic, and psychiatric abnormalities ranging from agitation, hallucinations, paranoia, and psychosis to seizures, hyperthermia, respiratory depression, bradycardia, hypotension, altered consciousness, and multiorgan complications. Synthetic cannabinoids and synthetic cathinones were prominently represented among psychiatric intoxication cases, while nitazene poisoning demonstrated variable naloxone requirements, including the need for prolonged infusion in selected patients. Xylazine exposure was mainly associated with central nervous system depression, bradycardia, hypotension, and respiratory compromise, particularly in the context of polysubstance use. The findings support a syndromic and physiology-first approach in which airway protection, ventilatory support, cardiovascular monitoring, temperature control, seizure management, treatment of severe agitation, correction of metabolic abnormalities, and selective antidotal therapy are prioritized according to the patient’s clinical condition. Persistent neuropsychiatric manifestations require reassessment after acute stabilization to differentiate transient intoxication from prolonged substance-induced psychiatric syndromes. An integrated approach involving emergency medicine, clinical toxicology, and psychiatry is essential for the effective management of these rapidly evolving intoxications.
Referencias
• Ball, N. S., Knable, B. M., Relich, T. A., Smathers, A. N., Gionfriddo, M. R., Nemecek, B. D., Montepara, C. A., Guarascio, A. J., Covvey, J. R., & Zimmerman, D. E. (2022). Xylazine poisoning: A systematic review. Clinical Toxicology, 60(8), 892–901. doi:10.1080/15563650.2022.2063135.
• Brunetti, P., Giorgetti, R., Tagliabracci, A., Huestis, M. A., & Busardò, F. P. (2021). Designer benzodiazepines: A review of toxicology and public health risks. Pharmaceuticals, 14(6), 560. doi:10.3390/ph14060560.
• Cheng, H.-C., Wang, T.-Y., Chang, C.-M., Liao, P.-H., & Chen, Y.-C. (2026). Fatal polydrug intoxication involving synthetic cathinones in Taiwan: A case series and emergency management implications. The Journal of Emergency Medicine, 83, 11–19. doi:10.1016/j.jemermed.2026.01.012.
• Daziani, G., Lo Faro, A. F., Montana, V., Goteri, G., Pesaresi, M., Bambagiotti, G., Montanari, E., Giorgetti, R., & Montana, A. (2023). Synthetic cathinones and neurotoxicity risks: A systematic review. International Journal of Molecular Sciences, 24(7), 6230. doi:10.3390/ijms24076230.
• Edinoff, A. N., Nix, C. A., Odisho, A. S., Babin, C. P., Derouen, A. G., Lutfallah, S. C., Cornett, E. M., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022). Novel designer benzodiazepines: Comprehensive review of evolving clinical and adverse effects. Neurology International, 14(3), 648–663. doi:10.3390/neurolint14030053.
• Mas-Morey, P., Visser, M. H. M., Winkelmolen, L., & Touw, D. J. (2013). Clinical toxicology and management of intoxications with synthetic cathinones (“bath salts”). Journal of Pharmacy Practice, 26(4), 353–357. doi:10.1177/0897190012465949.
• Mosca, A., Mancusi, G., Chiappini, S., Miuli, A., Cavallotto, C., Corkery, J. M., Di Petta, G., Pasino, A., Santovito, M. C., Marrangone, C., Vicinelli, M. C., Pettorruso, M., Martinotti, G., & Schifano, F. (2025). Novel psychoactive substances (NPS) as a risk factor for psychosis: A systematic review of the literature. Neuroscience & Biobehavioral Reviews, 179, 106431. doi:10.1016/j.neubiorev.2025.106431.
• Owusu-Antwi, P., Atodaria, P., Appiah-Kubi, E., Shah, Z., & Garcia, E. M. (2025). Management of xylazine toxicity, overdose, dependence, and withdrawal: A systematic review. The American Journal on Addictions, 34(6), 589–602. doi:10.1111/ajad.70051.
• Pourmand, A., Mazer-Amirshahi, M., Chistov, S., Li, A., & Park, M. (2018). Designer drugs: Review and implications for emergency management. Human & Experimental Toxicology, 37(1), 94–101. doi:10.1177/0960327117698542.
• Prete, M. M., Feitosa, G. T. B., Ribeiro, M. A. T., Fidalgo, T. M., & Sanchez, Z. M. (2025). Adverse clinical effects associated with the use of synthetic cannabinoids: A systematic review. Drug and Alcohol Dependence, 272, 112698. doi:10.1016/j.drugalcdep.2025.112698.
• Prosser, J. M., & Nelson, L. S. (2012). The toxicology of bath salts: A review of synthetic cathinones. Journal of Medical Toxicology, 8(1), 33–42. doi:10.1007/s13181-011-0193-z.
• Ricci, V., Chiappini, S., Martinotti, G., & Maina, G. (2026). Acute and long-term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review. Psychiatry Research, 360, 117056. doi:10.1016/j.psychres.2026.117056.
• Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical practice guidelines for assessment and management of patients with substance intoxication presenting to the emergency department. Indian Journal of Psychiatry, 65(2), 196–211. doi:10.4103/indianjpsychiatry.indianjpsychiatry_490_22.
• Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021). New/emerging psychoactive substances and associated psychopathological consequences. Psychological Medicine, 51(1), 30–42. doi:10.1017/S0033291719001727.
• Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020). New psychoactive substances: A review and updates. Therapeutic Advances in Psychopharmacology, 10, 2045125320967197. doi:10.1177/2045125320967197.
• Stangeland, M., Dale, O., & Skulberg, A. K. (2025). Nitazenes: Review of comparative pharmacology and antagonist action. Clinical Toxicology, 63(6), 393–406. doi:10.1080/15563650.2025.2504133.
• Taflaj, B., La Maida, N., Tittarelli, R., Di Trana, A., & D’Acquarica, I. (2024). New psychoactive substances toxicity: A systematic review of acute and chronic psychiatric effects. International Journal of Molecular Sciences, 25(17), 9484. doi:10.3390/ijms25179484.
• Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016). A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology, 54(1), 1–13. doi:10.3109/15563650.2015.1110590.
• Tracy, D. K., Wood, D. M., & Baumeister, D. (2017). Novel psychoactive substances: Types, mechanisms of action, and effects. BMJ, 356, i6848. doi:10.1136/bmj.i6848.
• Vandeputte, M. M., & Stove, C. P. (2025). Navigating nitazenes: A pharmacological and toxicological overview of new synthetic opioids with a 2-benzylbenzimidazole core. Neuropharmacology, 275, 110470. doi:10.1016/j.neuropharm.2025.110470.
